Using surrogate failure time data to increase cost effectiveness in clinical trials
From MaRDI portal
Publication:4299462
DOI10.1093/biomet/80.4.823zbMath0800.62706MaRDI QIDQ4299462
Michael R. Kosorok, Thomas R. Fleming
Publication date: 4 July 1994
Published in: Biometrika (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1093/biomet/80.4.823
martingale; censored data; linear rank statistic; multiple endpoints; asymptotic joint distribution; failure times; surrogate outcome; weighted log rank
62P10: Applications of statistics to biology and medical sciences; meta analysis
Related Items
Properties of A Nonparametric Test for Early Comparison of Treatments in Clinical Trials in the Presence of Surrogate Endpoints, Using categorical markers as auxiliary variables in log-rank tests and hazard ratio estimation, Some comments on efficiency gains from auxiliary information for right-censored data, Improving efficiency in clinical trials using auxiliary information: Application of a multi‐state cure model, Robust Covariate‐Adjusted Log‐Rank Statistics and Corresponding Sample Size Formula for Recurrent Events Data, Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials